Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.

Background: Early access program (formerly cohort Temporary Authorization for Use) was granted for trastuzumab deruxtecan (T-DXd) in France based on DESTINY-Breast01 trial which demonstrated its efficacy and safety in HER2-positive metastatic/unresectable breast cancer after ≥2 anti-HER2-based regimens received at metastatic stage.

Methods: This multicenter real-world early access program included HER2-positive metastatic/unresectable breast patients pretreated with at least two lines of anti-HER2 regimens who received T-DXd 5.4 mg/kg intravenously in monotherapy every 3 weeks.

Pleuro-pulmonary blastoma in a 45 year-old woman after Hodgkin's lymphoma: a case report.

Pleuro-pulmonary blastoma is a rare and aggressive intrathoracic mesenchymal tumor occurring in childhood. We report the exceptional case of a forty-five year-old woman, presenting with respiratory distress. She had previously been treated with chemotherapy and radiotherapy for Hodgkin lymphoma.

Gemcitabine-associated thrombotic microangiopathy in a patient with lung cancer: A case report.

Gemcitabine is frequently used for the treatment of a number of different cancer types. Gemcitabine-related thrombotic microangiopathy (TMA) has rarely been described, but it is a life-threatening complication. The incidence of the complication varies between 0.

Management of anemia and iron deficiency in a cancer center in France.

Purpose: Anemia affects most patients treated for cancer by chemotherapy. It is a known major contributor to fatigue and loss of quality of life and is likely to have a negative effect on prognosis and mortality from cancer. The main purpose of this study was to characterize the management of anemia and iron deficiency in a French oncology day-care center.